Positive Pain Data for Xenoport's RLS Drug

September 2009
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p5
The article reports on the impact of the positive result of the Phase IIb studies on the use of gabapentin prodrug on the shares of XenoPort Inc. in Santa Clara, California. It states that the investors are adding their shares to the stock of the company after the study on the use of gabapentin in reducing neuropathic pain with post-herpetic neuralgia shown positive result. It adds that the drug is now reviewed by the U.S. Food and Drug Administration (FDA) and will be sold under Solzira brand.


Related Articles

  • NME approval times increasing in the United States. Bouchie, Aaron // Nature Biotechnology;Jun2001, Vol. 19 Issue 6, p499 

    Reports on the time taken by the U.S. Food & Drug Administration (FDA) to approve the new molecular entities in 2000 as compared to 1999. Reasons for the lowering of the investor earning estimates; Efforts made by the FDA to increase efficiency of review times.

  • XenoPort Shares Collapse After FDA Rejects RLS Compound. Young, Donna // BioWorld Today;2/19/2010, Vol. 21 Issue 33, p1 

    This article reports on the decline posted by XenoPort Inc. shares on February 18, 2010 amid news that its partner GlaxoSmithKline PLC received a complete response letter from the U.S. Food and Drug Administration (FDA) for its application for Horizant indicated for moderate to severe primary...

  • Investor Underreaction to Earnings Surprises and Overreaction to Product News in the Drug Industry. Fischer, Dov // Journal of Business & Economic Studies;Fall2012, Vol. 18 Issue 2, p82 

    Prior studies documented that stock prices continue to drift in the direction of the initial shock of an earnings surprise for a period of between 3-12 months. This post-earningsannouncement drift (PEAD) represents a seminal finding of apparent investor underreaction to news. This study presents...

  • As Genzyme flounders, competitors and activist investors swoop in. Allison, Malorye // Nature Biotechnology;Jan2010, Vol. 28 Issue 1, p3 

    The article reports on the acceleration of approval of products of competing biotechnology manufacturers and the sale of stock by investors at Genzyme as the company faces viral contamination problem at its plant in Allston, Massachusetts. With the problem facing Genzyme, the U.S. Food and Drug...

  • Complete Response Letter Sinks Northfield.  // Bioworld Week;5/11/2009, Vol. 17 Issue 19, p3 

    The article reports on the impact of the complete response letter received by Evanston, Illinois-based Northfield Laboratories Inc. for its blood substitute product, PolyHeme. The company's shares decreased by more than 50 percent after it received a response letter from the U.S. Food and Drug...

  • PTI Stock Plunges On Talabostat Clinical Hold.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p3 

    The article reports on the decrease of trading value of stocks of the Point Therapeutics Inc. According to reports, shares of Point Therapeutics fell 68 percent to a 52-week low of 14 cent per share, after the U.S. Food and Drug Administration placed a hold on the company's talabostat clinical...

  • Did FDA Rejection of Lorcasin Lift Weight off Investors' Minds? Young, Donna // BioWorld Today;10/26/2010, Vol. 21 Issue 207, p1 

    The article reports that the investors were not affected by the decision of the U.S. Food and Drug Administration (FDA) to reject the weight-loss drug of Arena Pharmaceuticals Inc. called lorcaserin. Stock price of the company went up by 4 cents to 1.67 U.S. dollars each. Meanwhile, the FDA...

  • Auxilium Shares Jump on Good FDA Xiaflex Review.  // Bioworld Week;9/21/2009, Vol. 17 Issue 38, p3 

    The article reports on the impact of the positive review given by the U.S. Food and Drug Administration (FDA) on the use of Xiaflex on the shares of Auxilium Inc. It states that the positive review of FDA has driven the investors to increase their shares in Auxilium. It adds that the...

  • Investors Pan AbbVie's Offer. Investor's Business Daily // Investors Business Daily;3/6/2015, pA01 

    4 The drug giant's $21 bil offer for


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics